Biogen news. Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease

Multiple factors contributed to the greater exposure to aducanumab in the new analysis of the larger dataset, including data on a greater number of patients, a longer average duration of exposure to high dose, the timing of protocol amendments that allowed a greater proportion of patients to receive high dose, and the timing and pre-specified criteria of the futility analysis As a pioneer in the field of dementia treatment, Eisai is striving to not only develop next generation treatments but also to develop diagnosis methods and provide solutions
Sources: CoinDesk Bitcoin , Kraken all other cryptocurrencies Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released Biogen also manufactures and commercializes biosimilars of advanced biologics
Shares Sold Short The total number of shares of a security that have been sold short and not yet repurchased Shares of Cassava Sciences Inc
For more information about Eisai Co By better I mean trials conducted among individuals at earlier stages of the disease, or among those with positive beta-amyloid scans or those who have elevated levels of another key protein, tau, in their cerebrospinal fluid
To learn more, please visit and follow us on social media — , , , Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases
Take, for example, lovastatin Mevacor , the in 1987. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. The recommendation to stop the studies was not based on safety concerns. This work is timely if earlier identification of the disease means greater chances that therapy with aducanumab or other agents can help prevent, or at least modify, memory loss and other symptoms such as trouble doing everyday activities. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.